1083078-88-9

Basic information

• Product Name: 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-1-oxido-4-piperidinyl]-1,3-dihydro-2H-benziMidazol-2-one
• Synonyms: 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-1-oxido-4-piperidinyl]-1,3-dihydro-2H-benziMidazol-2-one;PiMozide N-Oxide
• CAS NO: 1083078-88-9
• Molecular Formula: C28H29F2N3O2-
• Molecular Weight: 477.5455664
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Nitric Oxide Reagents;Pharmaceuticals
• Mol File: 1083078-88-9.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-1-oxido-4-piperidinyl]-1,3-dihydro-2H-benziMidazol-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-1-oxido-4-piperidinyl]-1,3-dihydro-2H-benziMidazol-2-one(1083078-88-9)
• EPA Substance Registry System: 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-1-oxido-4-piperidinyl]-1,3-dihydro-2H-benziMidazol-2-one(1083078-88-9)

Safety Data

• Hazardous Substances Data: 1083078-88-9(Hazardous Substances Data)

Usage

Uses

Pimozide N-Oxide is an impurity of Pimozide (P447800) with hERG inhibitory activity. Pimozide impurity E.

Upstream product

• 2062-78-4 pimozide 

Relevant articles and documents

N-OXIDE-CONTAINING PHARMACEUTICAL COMPOUNDS

The invention provides a method of preparing a therapeutically active compound having reduced hERG activity, which method comprises: (a) selecting a non-N-oxide drug compound containing a basic tertiary amino group, wherein said non-N-oxide compound is known to have or is suspected of having a therapeutically unacceptable level of hERG inhibitory activity; (b) testing the non-N-oxide drug compound for hERG inhibitory activity; (c) reacting the non-N-oxide drug compound with an oxidising agent to form an N- oxide drug compound having an N-oxide at the basic tertiary amino group; (d) testing the N-oxide drug compound for hERG inhibitory activity; (e) testing the N-oxide drug compound for therapeutically useful activity; (f) comparing the hERG inhibitory activity of the N-oxide drug compound and non- N-oxide drug compound; and (g) when the N-oxide drug compound has therapeutically useful activity and has hERG activity which is at least ten fold less than the hERG inhibitory activity of the non-N-oxide drug compound, formulating the N-oxide drug compound for use in medicine. Also provided by the invention are novel compounds prepared by the aforementioned method and the use of the novel compounds in medicine.